Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the
emergence and development of antiangiogenic therapies to eliminate bleeding …

Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of …

Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple
arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct …

Hereditary haemorrhagic telangiectasia (HHT) is a complex, multisystemic vascular
dysplasia affecting approximately 85,000 European Citizens. In 2016, eight founding centres …

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia.
Care delivery for HHT patients is impeded by the need for laborious, repeated phenotyping …

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease,
is a rare disorder with a case prevalence as high as one in 5000, causing arteriovenous …

The potential of covert pulmonary arteriovenous malformations (PAVMs) to cause early
onset, preventable ischemic strokes is not well known to neurologists. This is evident by their …

CNS vascular malformation is an umbrella term that encompasses a wide variety of
pathologies, with a wide range of therapeutic and diagnostic importance. This range spans …

The abnormal vascular structures of hereditary hemorrhagic telangiectasia (HHT) often
cause severe anemia due to recurrent hemorrhage, but HHT causal genes do not predict the …

Background Antithrombotic therapy (anticoagulation and antiplatelet therapy) is frequently
needed in patients with hereditary hemorrhagic telangiectasia (HHT); however, data …